Literature DB >> 33436573

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.

Cyrielle Fougeroux1, Louise Goksøyr1,2, Manja Idorn3, Vladislav Soroka4, Sebenzile K Myeni5, Robert Dagil2,6, Christoph M Janitzek2, Max Søgaard4, Kara-Lee Aves2, Emma W Horsted2, Sayit Mahmut Erdoğan2,7, Tobias Gustavsson2,6, Jerzy Dorosz4, Stine Clemmensen4, Laurits Fredsgaard2, Susan Thrane1, Elena E Vidal-Calvo6, Paul Khalifé2, Thomas M Hulen2, Swati Choudhary2,6, Michael Theisen2,8, Susheel K Singh2,8, Asier Garcia-Senosiain2,8, Linda Van Oosten9, Gorben Pijlman9, Bettina Hierzberger4, Tanja Domeyer4, Blanka W Nalewajek4, Anette Strøbæk4, Magdalena Skrzypczak4, Laura F Andersson4, Søren Buus10, Anette Stryhn Buus10, Jan Pravsgaard Christensen10, Tim J Dalebout5, Kasper Iversen11, Lene H Harritshøj12, Benjamin Mordmüller13,14, Henrik Ullum11, Line S Reinert3, Willem Adriaan de Jongh1,4, Marjolein Kikkert5, Søren R Paludan3, Thor G Theander2, Morten A Nielsen15, Ali Salanti2,6, Adam F Sander16,17.   

Abstract

The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.

Entities:  

Year:  2021        PMID： 33436573     DOI： 10.1038/s41467-020-20251-8

Source DB:  PubMed          Journal:  Nat Commun        ISSN： 2041-1723            Impact factor:   14.919


  33 in total

1.  The COVID-19 vaccine development landscape.

Authors:  Tung Thanh Le; Zacharias Andreadakis; Arun Kumar; Raúl Gómez Román; Stig Tollefsen; Melanie Saville; Stephen Mayhew
Journal:  Nat Rev Drug Discov       Date:  2020-05       Impact factor: 84.694

2.  Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization.

Authors:  Jing Chen; Lin Miao; Jia-Ming Li; Yan-Ying Li; Qing-Yu Zhu; Chang-Lin Zhou; Hong-Qing Fang; Hui-Peng Chen
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

3.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 4.  SARS-CoV-2 Vaccines: Status Report.

Authors:  Fatima Amanat; Florian Krammer
Journal:  Immunity       Date:  2020-04-06       Impact factor: 31.745

5.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors:  Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal:  Science       Date:  2020-03-04       Impact factor: 47.728

6.  Immunogenicity of a DNA vaccine candidate for COVID-19.

Authors:  Trevor R F Smith; Ami Patel; Stephanie Ramos; Dustin Elwood; Xizhou Zhu; Jian Yan; Ebony N Gary; Susanne N Walker; Katherine Schultheis; Mansi Purwar; Ziyang Xu; Jewell Walters; Pratik Bhojnagarwala; Maria Yang; Neethu Chokkalingam; Patrick Pezzoli; Elizabeth Parzych; Emma L Reuschel; Arthur Doan; Nicholas Tursi; Miguel Vasquez; Jihae Choi; Edgar Tello-Ruiz; Igor Maricic; Mamadou A Bah; Yuanhan Wu; Dinah Amante; Daniel H Park; Yaya Dia; Ali Raza Ali; Faraz I Zaidi; Alison Generotti; Kevin Y Kim; Timothy A Herring; Sophia Reeder; Viviane M Andrade; Karen Buttigieg; Gan Zhao; Jiun-Ming Wu; Dan Li; Linlin Bao; Jiangning Liu; Wei Deng; Chuan Qin; Ami Shah Brown; Makan Khoshnejad; Nianshuang Wang; Jacqueline Chu; Daniel Wrapp; Jason S McLellan; Kar Muthumani; Bin Wang; Miles W Carroll; J Joseph Kim; Jean Boyer; Daniel W Kulp; Laurent M P F Humeau; David B Weiner; Kate E Broderick
Journal:  Nat Commun       Date:  2020-05-20       Impact factor: 14.919

Review 7.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

8.  Bacterial superglue enables easy development of efficient virus-like particle based vaccines.

Authors:  Susan Thrane; Christoph M Janitzek; Sungwa Matondo; Mafalda Resende; Tobias Gustavsson; Willem Adriaan de Jongh; Stine Clemmensen; Will Roeffen; Marga van de Vegte-Bolmer; Geert Jan van Gemert; Robert Sauerwein; John T Schiller; Morten A Nielsen; Thor G Theander; Ali Salanti; Adam F Sander
Journal:  J Nanobiotechnology       Date:  2016-04-27       Impact factor: 10.435

9.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Authors:  Wanbo Tai; Lei He; Xiujuan Zhang; Jing Pu; Denis Voronin; Shibo Jiang; Yusen Zhou; Lanying Du
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

10.  Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.

Authors:  Eun Kim; Geza Erdos; Shaohua Huang; Thomas W Kenniston; Stephen C Balmert; Cara Donahue Carey; V Stalin Raj; Michael W Epperly; William B Klimstra; Bart L Haagmans; Emrullah Korkmaz; Louis D Falo; Andrea Gambotto
Journal:  EBioMedicine       Date:  2020-04-02       Impact factor: 8.143
View more
  26 in total

Review 1.  A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases.

Authors:  Mohammad Sharifzadeh; Negar Mottaghi-Dastjerdi; Mohammad Soltany Rezae Raad
Journal:  Iran J Pharm Res       Date:  2022-05-09       Impact factor: 1.962

2.  A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering.

Authors:  Jingen Zhu; Neeti Ananthaswamy; Swati Jain; Himanshu Batra; Wei-Chun Tang; Douglass A Lewry; Michael L Richards; Sunil A David; Paul B Kilgore; Jian Sha; Aleksandra Drelich; Chien-Te K Tseng; Ashok K Chopra; Venigalla B Rao
Journal:  Sci Adv       Date:  2021-09-08       Impact factor: 14.957

3.  SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly.

Authors:  Susan K Vester; Rolle Rahikainen; Irsyad N A Khairil Anuar; Rory A Hills; Tiong Kit Tan; Mark Howarth
Journal:  Nat Commun       Date:  2022-06-28       Impact factor: 17.694

Review 4.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

Review 5.  VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants.

Authors:  Wasim A Prates-Syed; Lorena C S Chaves; Karin P Crema; Larissa Vuitika; Aline Lira; Nelson Côrtes; Victor Kersten; Francisco E G Guimarães; Mohammad Sadraeian; Fernando L Barroso da Silva; Otávio Cabral-Marques; José A M Barbuto; Momtchilo Russo; Niels O S Câmara; Gustavo Cabral-Miranda
Journal:  Vaccines (Basel)       Date:  2021-11-30

Review 6.  Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review.

Authors:  Fatima Akram; Ikram Ul Haq; Amna Aqeel; Zeeshan Ahmed; Fatima Iftikhar Shah; Ali Nawaz; Javaria Zafar; Rukhma Sattar
Journal:  J Virol Methods       Date:  2021-11-24       Impact factor: 2.014

Review 7.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

Review 8.  Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.

Authors:  Yury Valdes-Balbin; Darielys Santana-Mederos; Françoise Paquet; Sonsire Fernandez; Yanet Climent; Fabrizio Chiodo; Laura Rodríguez; Belinda Sanchez Ramirez; Kalet Leon; Tays Hernandez; Lila Castellanos-Serra; Raine Garrido; Guang-Wu Chen; Dagmar Garcia-Rivera; Daniel G Rivera; Vicente Verez-Bencomo
Journal:  ACS Cent Sci       Date:  2021-04-19       Impact factor: 14.553

Review 9.  Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases.

Authors:  Hasnat Tariq; Sannia Batool; Saaim Asif; Mohammad Ali; Bilal Haider Abbasi
Journal:  Front Microbiol       Date:  2022-01-03       Impact factor: 5.640

Review 10.  SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.

Authors:  Daniel Martínez-Flores; Jesús Zepeda-Cervantes; Adolfo Cruz-Reséndiz; Sergio Aguirre-Sampieri; Alicia Sampieri; Luis Vaca
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.